Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice.

Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. · 2019

Read Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice. by Choudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7025531.txt.

Introduction

Choudhari and co-authors review plant chemicals in cancer treatment for Frontiers in Pharmacology. Cancer remains a leading cause of death worldwide. Decades of synthetic drug development have not greatly lifted overall survival, so researchers keep looking to natural compounds. Plants supply many proven cancer drugs, including taxol relatives, vinca alkaloids, and podophyllotoxin relatives.

These phytochemicals act through several routes. They can boost antioxidant defences, neutralise carcinogens, slow cell division, trigger cell-cycle arrest and apoptosis, and adjust the immune system. The review describes the active compounds, their drug actions, and their molecular targets. It also maps recent trends and gaps in discovery work, arguing that plant chemistry still holds untapped leads for new cancer medicines.

Catalog record

CREATORChoudhari AS, Mandave PC, Deshpande M, Ranjekar P, Prakash O.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE83 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7025531

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Phytochemicals in Cancer Treatment: From Preclinical Studies to Clinical Practice By Amit S. Choudhari, Pallavi C. Mandave, Manasi Deshpande, Prabhakar Ranjekar, Om Prakash Published in: Frontiers in Pharmacology DOI: 10.3389/fphar.2019.01614 ABSTRACT Cancer is a severe health problem that continues to be a leading cause of death worldwide. Increasing knowledge of the molecular mechanisms underlying cancer progression has led to the development of a vast number of anticancer drugs. However, the use of chemically synthesized drugs has not significantly improved the overall survival rate over the past few decades. As a result, new strategies and novel chemoprevention agents are needed to complement current cancer therapies to improve efficiency. Naturally occurring compounds from plants known as phytochemicals, serve as vital resources for novel drugs and are also sources for cancer therapy. Some typical examples include taxol analogs, vinca alkaloids such as vincristine, vinblastine, and podophyllotoxin analogs. These phytochemicals often act via regulating molecular pathways which are implicated in growth and progression of cancer. The specific mechanisms include increasing antioxidant status, carcinogen inactivation, inhibiting proliferation, induction of cell cycle arrest and apoptosis; and regulation of the immune system. The primary objective of this review is to describe what we know to date of the active compounds in the natural products, along with their pharmacologic action and molecular or specific targets. Recent trends and gaps in phytochemical based anticancer drug discovery are also explored. The authors wish to expand the phytochemical research area not only for their scientific soundness but also for their potential druggability. Hence, the emphasis is given to information about anticancer phytochemicals which are evaluated at preclinical and clinical level. INTRODUCTION Cancer is a major public health problem that has a significant global impact on both developed and developing countries. In 2018, an estimated 18.1 million new cases of cancer occurred worldwide which are likely to increase to 23.6 million new cases each year by 2030 (Bray et al., 2018). Considering the high profile nature of the disease, its treatment has been a constant struggle with relatively less success. Currently available options for cancer treatment involve surgical removal and radiation treatment of the large accumulated biomass of cancer, typically followed by systemic chemotherapy treatment for maintenance. The primarily available chemotherapeutic agents include antimetabolites (e.g., methotrexate), DNA-interactive agents (e.g., cisplatin, doxorubicin), anti-tubulin agents (taxanes), hormones, and molecular targeting agents (Nussbaumer et al., 2011). The major disadvantages of chemotherapy are recurrence of cancer, drug resistance, and toxic effects on non-targeted tissues that can restrain the use of anticancer drugs and thus impair patient’s quality of life. To overcome the problems of present therapy, search for new promising anticancer agents with better efficacy and lesser side effects continues. Phytochemicals and derivatives present in plants are promising options to improve treatment efficiency in cancer patients and decrease adverse reactions. A number of these phytochemicals are naturally occurring biologically active compounds with significant antitumor potential. The development of effective and side-effects free phytochemical based anticancer therapy begins with the testing of natural extracts (from dry/wet plant material) for potential anticancer biological activity followed by purification of active phytochemicals based on bioassay-guided fractionation and testing for in vitro and in vivo effects. In the present review, an attempt has been made to gather information specifically about the anti-cancer phytochemicals that are evaluated at preclinical and clinical levels as well as those available in the market, until now. In preclinical section, we have reviewed the phytochemicals with a reported in vivo activity. This review further highlights phytochemicals which are assessed at preclinical level and also mentions some phytochemicals which are in the clinical trials along with the brief information on the presently used plant-based anticancer drugs. PLANT DERIVED DRUGS: A HISTORICAL PERSPECTIVE Plants have been used to treat various disease aliment from time immemorial. Ayurveda, Traditional Indian Medicine (TIM), and the Traditional Chinese Medicine (TCM) remain the most ancient (4500 BC) yet living traditions. In the ancient period, the knowledge of selection of right plants, a specific time for their collection, method of drug preparation with their specific use was transferred verbally from one generation to the next generation. The folklore system has documented all parameters about the drugs and their specific uses in the disease conditions. These drugs were prepared as tinctures, teas, powders, poultices, decoctions, and other types of formulations (Ogbonna et al., 2012; Fridlender et al., 2015) which were the most common methods of drug preparation until 18th century. Unfortunately, none of them could fit into the modern scientific definition of a drug. With advances in organic chemistry and chemical analysis, an analytical investigation of active components of medicinal plants and herbal remedies was pursued in late 18th or early 19th centuries, which opened the doors toward the isolation/purification and characterization of numerous active principles of plants. This increased the pace of drug discovery and led to a miracle innovation in the medical field. The first breakthrough which launched the first generation of drugs came with the isolation of analgesic (pain killing) drugs morphine from the plant Papaver somniferum. Later, many well-defined 20th century drugs were derived from plants, including salicylic acid, the precursor of aspirin (Salix sp.), cocaine (Erythroxylum coca), quinine (Cinchona officinalis), digitoxin (Digitalis purpurea and Digitalis lanata), and many others with pharmaceutical and clinical potential (Newman et al., 2000; Butler, 2004; Ogbonna et al., 2012). Over the period from around 1981 to the end of 2014, more than half of all approved small‐molecule drugs originated from natural products, where they served as drug precursors, templates for synthetic modification, and pharmacological probes (Newman and Cragg, 2016). This in itself demonstrates the enormous medicinal potential of plants that has been known for thousands of years in traditional medicine. A few commercially available plant-derived compounds used against various diseases are listed in Table 1 . [Table: List of commercially available plant derived drugs on various diseases.] PHYTOCHEMICALS WITH ANTICANCER PROPERTIES Scientific evidences indicate that phytochemicals have significant antitumor potential. Approximately, 50% of approved anticancer drugs from 1940 to 2014 originate from natural products or directly derived therefrom (Newman and Cragg, 2016). Some of the remarkable anticancer phytochemicals in this regard are describe in the present review. These phytochemicals have been tested for anti-cancer efficacy at both in vitro and in vivo levels. They possess complementary and overlapping mechanisms to slow down the carcinogenic process by scavenging free radicals (Lee et al., 2013), suppressing survival and proliferation of malignant cells (Yan et al., 2018), as well as diminishing invasiveness and angiogenesis of tumors (Lu et al., 2018a). They exert wide and complex range of actions on different molecular targets and signal transduction pathways including membrane receptors (Deng et al., 2017), kinases (Dou et al., 2018), downstream tumor-activator or -suppressor proteins (Adams et al., 2010), transcriptional factors (Zhang et al., 2017b), microRNAs (miRNAs) (Cojocneanu et al., 2015), cyclins, and caspases (Yan et al., 2018). PHYTOCHEMICALS IN PRE-CLINICAL TRIALS In a bench to bedside drug development process, meticulous use of preclinical screening models can results into potential lead compounds for anticancer drug development with extensive data on preliminary efficacy, toxicity, pharmacokinetic, and safety information which help to decide whether a molecule should be taken further for clinical trials. In the context of this review, abundant evidence has been

Read the complete text